Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Topics : Eye diseases
  • Topics : Drug therapy
  • Active substance : prednisolone
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Otorhinolaryngologic diseases (1)
    • Plus ...
      • Nose and sinus diseases (1)
    • Eye diseases (1)
    • Nervous system diseases (1)
    • Plus ...
      • Nervous system cancers (1)
    • Skin and connective tissue diseases (1)
    • Pain - Inflammation (1)
    • Musculoskeletal diseases (1)
    • Plus ...
      • Joint and rheumatic diseases (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Date
  • Last five years (1)
Language
  • Français (1)
Active substance
  • prednisolone (1)

Drugs, devices and medical acts - 1 result

  • HYDROCORTANCYL (prednisolone (acétate de))

    Medicine - Posted on 12/4/2018 - Mis à jour le 12/6/2019
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
x7APseUtbXLxqzgP